AACR Annual Meeting

A post hoc analysis shows significantly improved ORR and PFS in advanced NSCLC with higher AFM24 exposure, supporting optimized dosing strategies.

Ahmad Tarhini, MD, PhD, provides data into his research looking at inherited genetic variations and genetic ancestry in patients with high-risk melanoma.

Adagrasib shows initial promise, tolerability, and encouraging response rates in STK11/KRAS G12C-mutant lung cancer.

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.

Ahmad Tarhini, MD, PhD, discusses inherited genetic variations and genetic ancestry, particularly for patients with high-risk melanoma.

Invikafusp alfa elicited clinically meaningful antitumor activity in patients with advanced solid tumors resistant to anti–PD-1/PD-L1 agents.

Runimotamab plus trastuzumab resulted in positive clinical activity and tolerability over runimotamab alone in patients with HER2-positive breast cancer.

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety profile with strong antitumor evidence.

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, including TKD and non-TKD mutations.

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head and neck cancer per KEYNOTE-689, introducing a potential new standard of care.

Based on the encouraging efficacy signals of SOT101 plus pembrolizumab in these heavily pretreated patients with advanced solid tumors in the AURELIO-03 study, the AURELIO-04 trial is planned.

Molecular characteristics associated with resistance to CD19-directed chimeric antigen receptor T-cell therapy for pediatric acute lymphoblastic leukemia can hopefully improve patient selection and eligibility for therapy.

Promising T-cell responses and safety has been shown with the CoVac-1 vaccine in patients with cancer who have disease- or treatment-related immunoglobulin deficiency.

Results from a post-hoc exploratory analysis of the TALAPRO-1 study signal that high genomic loss of heterozygosity may be assiciated with enhanced response to talazoparib in patients with metastatic castration-resistant prostate cancer.

Findings of CheckMate 816 show improved event-free survival and partial complete response and promising overall survival results with the use of neoadjuvant nivolumab in combination with chemotherapy for patients with resectable NSCLC.

Results from the phase 2 CheckMate-848 study show that nivolumab in combination and ipilimumab may be effective for the treatment of advanced or metastatic tumor mutational burden–high solid tumors that were refractory to standard therapies.

According to new data, different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects has demonstrated early efficacy.

Sotorasib continues to wow in the phase 1/2 CodeBreaK 100 trial of patients with KRAS G12C–mutant non–small cell lung cancer.

According to Tanjina Kader, PhD, 12% of patients in the cohort who developed new, independent primary tumors raised the question of whether using these genetic biomarkers for prediction of recurrence is a good idea.

Preclinical research indicates that anti-mesothelin chimeric antigen receptor T cells may be more effective than gavocabtagene autoleucel in mesothelin-expressing tumors.

Prolonged periods of radiographic and clinical improvement in children and young adults with H3K27M diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas has been shown with GD2-directed chimeric antigen receptor T cells.

The bispecific antibody therapy AMF13 combined with preactivated and expanded natural killer cells showed encouraging activity in patients with heavily pretreated lymphoma.

Four-year follow-up data from the KEYNOTE-042 show promising survival and durable response in patients with non–small cell lung cancer.

Evidence for on-target activity of temferon has been demonstrated in patients with glioblastoma, according to the phase 1/2a TEM-GBM study.

According to a phase 1/2 study, nivolumab plus PD-L1/IDO peptide vaccine may be effective for the treatment of patients with metastatic melanoma.

For patients with metastatic breast cancer, research suggests that utilizing a multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data may be feasible and better than DNA sequencing alone.

In the phase 2 C-144-01 trial, patients had durable responses to treatment with the tumor-infiltrating lymphocyte lifileucel after more than 28 months of follow-up.

For the treatment of patients with HER2-amplified gastric cancers in addition to those with HER2 moderate-, low-, and non-expressing disease, trastuzumab deruxtecan has shown to be an effective therapeutic option.

In NRG1 fusion–positive cell lines, zenocutuzumab demonstrated blockage of growth and cell death, as well as tumor shrinkage and durable tumor regression in multiple cancers when used in NRG1 fusion–positive patient-derived xenografts.